Abstract
Background
Maternal microchimeric cells (MMc) transfer across the placenta during pregnancy. Increased levels of MMc have been observed in several autoimmune diseases including type 1 diabetes but their role is unknown. It has been suggested that MMc are 1) effector cells of the immune response, 2) targets of the autoimmune response or 3) play a role in tissue repair. The aim of this study was to define the cellular phenotype of MMc in control (n = 14) and type 1 diabetes pancreas (n = 8).
Methods
Using sex chromosome-based fluorescence in-situ hybridization, MMc were identified in male pancreas and their phenotype determined by concomitant immunofluorescence.
Results
In normal pancreas, MMc positive for endocrine, exocrine, duct and acinar markers were identified suggesting that these cells are derived from maternal progenitors. Increased frequencies of MMc were observed in type 1 diabetes pancreas (p = 0.03) with particular enrichment in the insulin positive fraction (p = 0.01). MMc did not contribute to infiltrating immune cells or Ki67+ islet cell populations in type 1 diabetes.
Conclusion
These studies provide support for the hypothesis that MMc in human pancreas are derived from pancreatic precursors. Increased frequencies of MMc beta cells may contribute to the initiation of autoimmunity or to tissue repair but do not infiltrate islets in type 1 diabetes.
Introduction
It is generally accepted that islet autoimmunity results from loss of tolerance to pancreatic self-peptides very early in life but despite decades of research, the origins of autoimmunity remain obscure. Birth cohort studies agree that seroconversion to insulin autoantibody positivity occurs from the age of 6 months onwards [1] raising the possibility that pre- or neonatal events may influence autoimmunity. The transfer of cells from mother to child in pregnancy represents the earliest immunological insult for the developing fetus. Maternal cells induce fetal CD4+CD25highFoxP3+Tregs that suppress anti-maternal immunity with effects that remain detectable into adulthood [2]. This suggests the active maintenance of immune tolerance to genetically distinct maternal cells in health and is supported by the observation of improved survival of renal transplants from sibling donors who share the non-inherited maternal HLA with the recipient [3].
Over the last decade, elevated levels of maternal cells have been reported in several autoimmune diseases (reviewed in [4], [5]) with several different hypotheses proposed; some suggest that MMc are effector cells of the immune response [6], others that semi-allogeneic MMc in specific host tissues may act as triggers of autoimmunity [7] while it has also been postulated that some MMc, like fetal microchimeric cells, may play a role in regeneration of damaged tissues [8]. We previously observed increased levels of MMc in the pancreas and periphery of individuals with type 1 diabetes [9], [10]. Phenotyping of MMc was limited however because of difficulties combining FISH and immunofluorescence on historical autopsy samples as well as availability of well-matched controls.
In this study, we determined the frequency and phenotypes of MMc in pancreatic autopsy sections from normal individuals, as well as in males with type 1 diabetes and age-matched controls.
Materials and Methods
Ethics statement
Full written informed consent was available for all samples tested and appropriate local ethical approval was obtained from Southmead Research Ethics Committee (Ref:04/Q2002/35:The role of maternal microchimerism in type 1 diabetes). The samples used in this study were obtained from the following tissue banks: Network for pancreatic orgon donors with diabetes (nPOD - http://www.jdrfnpod.org/), the Glasgow Tissue Bank (http://www.nhsggc.org.uk/content/default.asp?page=s1685) and the Erasmus Tissue Bank (http://www.erasmusmc.nl/pathologie/clinicalpathology/tissuebank)”.
Human tissues to phenotype MMc in control pancreas
To determine phenotype of MMc in normal human pancreas, 4 µm sections of 9 formalin fixed and paraffin embedded (FFPE) control male human pancreases provided by Dr. Ronald de Krijger, Erasmus University, Rotterdam, The Netherlands, were examined (Table 1, controls 6 to 14). These tissues were considered normal on pathological examination and no history was available on twin pregnancies or transfusion history. Female tissues were excluded because the detection of maternal cells was based on sex-chromosome discrimination.
Table 1. Age, duration of diabetes and inflammatory status in pancreases from individuals with type 1 diabetes, 5 age matched controls for T1D cases, and 9 control pancreases.
nPOD Case ID | Age | Duration of diabetes | Insulin positivity | Beta cell destruction status | |
T1D case 1 | 6051 | 20.3 years | 13 years | Yes | Mild infiltration, partial beta cell destruction |
T1D case 2 | 6084 | 14.2 years | 4 years | Yes | Mild to heavy infiltration, partial beta cell destruction |
T1D case 3 | 6069 | 22.6 years | 7 years | Yes | Mild infiltration, partial beta cell destruction |
T1D case 4 | 6180 | 27.1 years | 11years | No | Complete beta cell destruction |
T1D case 5 | 6081 | 31.4 years | 15 years | Yes | Partial beta cell destruction |
T1D case 6 | 6088 | 31.2 years | 5 years | Yes | Partial beta cell destruction |
T1D case 7 | - | 15 years | 6 months | Yes | Partial beta cell destruction |
T1D case 8 | - | 17 years | Recent onset | Yes | Partial beta cell destruction |
Control 1 for T1D case 1 | 6174 | 20.8 years | - | Yes | - |
Control 2 for T1D case 2 | 6099 | 14.2 years | - | Yes | - |
Control 3 for T1D case 3 | 6162 | 22.7 years | - | Yes | - |
Control 4 for T1D case 4 | 6055 | 27 years | - | Yes | - |
Control 5 (for T1D cases 5 and 6) | 6030 | 30.1 years | - | Yes | - |
Control 6 | - | 36–40w gestational | - | Yes | - |
Control 7 | - | 37w gestational | - | Yes | - |
Control 8 | - | 40w2days gestational | - | Yes | - |
Control 9 | - | 6 weeks | - | Yes | - |
Control 10 | - | 21 months | - | Yes | - |
Control 11 | - | 3 years | - | Yes | - |
Control 12 | - | 4 years | - | Yes | - |
Control 13 | - | 11 years | - | Yes | - |
Control 14 | - | 13 years | - | Yes | - |
T1D and age matched normal human pancreas
4 µm sections of FFPE male human pancreases from 6 long standing T1D patients (T1D cases 1 to 6) and 5 aged matched controls were obtained from the Network for Pancreatic Organ Donors (nPOD) and are listed with nPOD IDs in Table 1. Two recent onset T1D pancreases (T1D cases 7 and 8) were provided by Dr Alan Foulis, Glasgow Royal Infirmary, Glasgow, UK.
Fresh human islets
Human islets with estimated 5–10,000 IEQ, purity 70–80% isolated from a 59-year-old male cadaveric donor were obtained from the Islet Isolation Centre, University of Oxford, Oxford, UK. Individual islets were cultured on type I collagen coated coverslips in CMRL1066 basal medium with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin at 37°C for FISH and immunofluorescence.
Concomitant fluorescence in situ hybridization (FISH) and immunofluorescence
Paraffin sections were deparaffinized in a xylene series followed by heat mediated antigen retrieval. Slides were then dehydrated in an ethanol series (70%, 80% and 100%) and air dried. Frozen sections were fixed in ice-cold pure ethanol for 10 min and air-dried prior to in situ hybridization. Purified human islets were cultured on rat tail type I collagen coated coverslips. They were fixed in 1% paraformaldehyde for 15 min, then simultaneously permeabilized and blocked in 0.1% (w/v) saponin (Sigma, S4521), 3% BSA solution for 45 min, and subsequently dehydrated in ethanol series. After pre-treatments, tissue sections or cell preparations were incubated with X/Y chromosome FISH probes (Vysis CEP X Spectrum Orange™/Y Spectrum Green™ Direct labelled Fluorescent DNA probe, Abbot Molecular Inc., Des Plaines, IL) as described previously [10]. To study aneuploidy/polyploidy, the CEP 18 probe (Abbot Molecular Inc.) was used in combination with the X/Y probe. After post-hybridization washes, sections or cells were incubated with primary antibodies (and controls as appropriate) specific for insulin (DAKO, A0564), glucagon (DAKO, A0565), somatostatin (Santa Cruz, SC-13099), GATA4 (Santa Cruz, SC-1237), Cytokeratin-19 (Abcam, Ab9221), Ki67 (Abcam, Ab833), CD68 (DAKO, m0876), CD45 (DAKO, M0701), nestin (Millipore MAB5326), or CD34 (Invitrogen, 073403) for 2 hrs at 37°C. After probing with the corresponding fluorescent secondary antibody for 1 hr at room temperature, sections were washed three times in 1× PBS solution, dehydrated, and counterstained with DAPI permanent mounting media (VECTASHIELD®, Vector laboratories, CA).
Image analysis
Fluorescent imaging
Images were captured using an Olympus BX41 fluorescent microscope fitted with an AxioCam MRm digital camera (Zeiss, Germany). The X and Y chromosomes were analyzed using the ISIS fluorescent imaging software (Zeiss, Germany) designed for FISH.
Confocal microscopy
To confirm MMc frequencies, pancreatic tissue sections were screened using a Leica SP5 confocal imaging system at the Wolfson Bioimaging Facility, School of Biochemistry, University of Bristol, UK. Z-stack images of each tissue section were analyzed for FISH and immunofluorescence to allow visualization of X and Y chromosome signals in all planes of the nucleus.
Counting strategy
FISH signals were checked in individual filter channels to ensure signal fidelity and that the visualization of two red dots representing two copies of the X chromosome was not caused by immunofluorescence cross talk. Only cells that showed clear XY (red and green dot) or XX (two red dots) signals within single nuclei were counted. Any cells with overlapping nuclei were excluded from the analysis. X chromosome “splits” that occasionally appeared as two juxtapositional dots due to DNA breakage were not considered as XX signals. A FISH success rate (the frequency of nuclei with two clear signals visible) of greater than 60% was required before further analysis.
All T1D and matched control tissues were stained for FISH and insulin. Overall, as many nuclei as possible were counted (>1000 at least), including at least 20 islets per section. MMc were counted in insulin positive and insulin negative cell fractions. For T1D case 1, 2, and 3, MMc were also examined in CD45+ population. An additional independent, blinded scorer reviewed each candidate female cell.
Statistical analysis
Differences in MMc frequencies between T1D patients and controls were analysed using two-tailed t tests (Graphpad Prism 5).
Results
MMc are endocrine and exocrine cells in normal pancreas
MMc were identified in all normal pancreas samples tested. Insulin, glucagon, and rarely somatostatin positive MMc were present in the islets of Langerhans, suggesting that they were beta cells, alpha cells, and delta cells of normal endocrine compartments (Figure 1 a–c). MMc were also identified outside the islets. To determine whether they were acinar cells, the expression of GATA4, a transcription factor specific for acinar cells in pancreas was examined [11] [12] and GATA4 positive MMc were observed (Figure 1 d). In the ductal epithelium, rare cytokeratin-19 positive MMc were detected. Co-staining for cytokeratin-19 and insulin demonstrated occasional insulin positive cells close to the duct but these were not MMc (Figure 1 e). Additionally, rare CD34+ MMc were scattered in the strands of microvasculature (Figure 1 f), co-stained for VE-cadherin (data not shown) suggesting that these cells are endothelial in origin.
MMc in fresh human islets
MMc were demonstrated in intact human islets cultured for 7 days and in islet-derived cells cultured for 43 days at passage 5 (Figure 2 a and b). Concomitant immunolabeling showed an MMc positive for nestin (Figure 2 c), an intermediate filament that is transiently expressed by islet cells that undergo dedifferentiation. This implies that in vitro, MMc propagate and dedifferentiate as host cells do [13], [14].
MMc verification: confocal microscopy, aneuploidy/polyploidy and phagocytosis
XY chromosome was combined with chromosome 18 FISH determine whether cells identified as MMc could result from aneuploidy/polyploidy. A typical MMc contained XX, 1818 signals (Figure S1), indicating the MMc are diploid, not polyploid. Finally, it is possible that XX cells in T1D islets could result from phagocytosis but again co-staining MMc with macrophage marker proved that this was not the case (Figure S2).
Fetal MMc are capable of replicating
Some MMc were present in close proximity (Figure 3 a). Given the extremely low frequencies of MMc, we questioned whether some MMc were able to proliferate. In agreement with this, an MMc positive for the replication marker, Ki67 was identified in exocrine tissue from a normal 37-week gestational pancreas, suggesting that these cells are capable of undergoing mitosis during development (Figure 3 b and c).
MMc levels are higher in T1D pancreas overall, and in the insulin positive compartment, compared with age-matched controls
As shown in Figure 4 a, the frequencies of total pancreatic MMc were significantly higher in T1D (0.68±0.07%, n = 6) compared with control pancreas (0.39±0.09%, n = 5) (two tailed t test, p = 0.033). Analysis of insulin positive MMc revealed enrichment of maternal cells among the beta cell fraction in the islets of T1D pancreases (2.34±0.5%, n = 5 in T1D samples vs. 0.66±0.2%, n = 5 in control samples) (two tailed t test, p = 0.0166) (Figure 4b). Nuclei containing XXY and/or XYY aneuploidy were observed at similar rates in T1D and control pancreas (0.6±0.1% in T1D and 0.64±0.3% in controls) (Table 2).
Table 2. Frequencies of MMc in T1D and control male human pancreases.
Total cells | Total No. MMc/(%) | No. of insulin+ MMc/(%) | Anueploidy/Polyploidy (%) | |
T1D case 1 | 2865 | 29/1.01% | 12/4.27% | 1.08% |
T1D case 2 | 2417 | 18/0.74% | 11/2.44% | 0.78% |
T1D case 3 | 2956 | 17/0.58% | 10/1.62% | 0.74% |
T1D case 4 | 2666 | 18/0.68% | 6/1.30% | 0.15% |
T1D case 5 | 2321 | 12/0.52% | 0/0% | 0.47% |
T1D case 6 | 2330 | 13/0.56% | 7/2.09% | 0.43% |
Control 1 | 2130 | 6/0.28% | 2/0.53% | 1.88% |
Control 2 | 1577 | 6/0.38% | 2/0.38% | 0.45% |
Control 3 | 1483 | 11/0.74% | 7/1.4% | 0.27% |
Control 4 | 1571 | 3/0.19% | 1/0.24% | 0.45% |
Control 5 | 2620 | 9/0.34% | 7/0.75% | 0.15% |
MMc do not infiltrate the islets in autoimmune diabetes
To assess whether maternal cells are present in insulitis, two recent onset T1D pancreases, three long-standing T1D pancreases, and three age-matched control pancreases underwent X/Y FISH and CD45 staining. In all recent onset and long standing pancreases examined, >1400 cells were scored per sample. CD45+ frequencies varied from 1–20% in T1D pancreas. All CD45+ leukocytes observed contained X and Y chromosomes (Figure 6a and Table S1). In age-matched control male pancreases, CD45+ cells were mostly located in the vasculature (frequencies between 0.2–2.06%) and none was female.
Replicating cells in T1D pancreas are not MMc
As shown on Figure 5, MMc are over-represented in some T1D islets. To determine whether these MMc could be replicating cells, T1D and control sections with intact islets were co-stained with Ki67, insulin and CD45. In T1D case 2, Ki67 positive replicating cells were observed in both endocrine and exocrine tissue but proliferating endocrine cells were not present in an age-matched control (1.09% of 8055 cells examined compared with 0.15% of 6688 cells examined). Proliferating lymphocytes were excluded by CD45 co-staining (Figure 6 b). A total of 27 islets were examined in the T1D tissue, 59 endocrine cells were Ki67 immunopositive and 12 (20%) were dual positive for insulin. X/Y FISH analysis showed that all Ki67 positive cells were male (Figure 6 c). In age matched control tissue, 29 islets were examined and no replicating endocrine cells were detected. 10 scattered Ki67+ cells were found in the acini, which were all male cells.
Discussion
The phenomenon of bi-directional cell trafficking across the placental barrier is well established but the biological consequences remain elusive. Chimeric cells of maternal origin reside in the periphery and in multiple somatic tissues. Previously, we detected the presence of MMc in male human pancreas and increased levels in type 1 diabetic pancreas [9], [10]. Here, we demonstrate that MMc exist in all pancreatic cell subsets including the endocrine, exocrine, and vascular endothelial lineages, implying that they are likely to be terminally differentiated cells derived from maternal multi/pluripotent progenitors and suggesting maternal stem cell differentiation in the developing pancreas. The frequency of MMc is increased in type 1 diabetes pancreases with particular enrichment in beta cells. This enrichment was not due to infiltrating immune cells or to islet cell replication.
A strength of this study was the availability of high quality type 1 diabetes and control tissue for analysis and specific methodologies to detect and phenotype cells with two X chromosomes in male tissue. There are also some limitations: insulin is a good but not perfect marker of beta cell phenotype as islets are cell dense and cytoplasmic staining can be difficult to assign to a given nucleus. Analysing maternal cell frequency by counting several thousand cells per section using confocal imaging is labour intensive and although each MMc has been confirmed by an independent second scorer, a degree of subjectivity remains. Similarly, polyploid beta cells, which have previously been described in human pancreas [15], could be potentially erroneously classified as XX signals. XY chromosome FISH was therefore combined with chromosome 18 FISH to determine whether 4 copies of chromosome 18 could be identified in “MMc”. These experiments did not identify a single miscalled MMc. Finally, it is possible that XX cells in T1D islets could result from phagocytosis but again our data showed that this was not the case. Unequivocal identification of the ‘maternal origin’ of MMc by single cell laser capture and DNA profiling are under development and would eliminate these queries in future studies. Our analysis focused on longstanding diabetes and we found higher frequencies of insulin positive MMc compared with the recent onset case reported previously by Nelson and colleagues [9]. While this could suggest that MMc frequency increases after diagnosis or that MMc are resistant to lysis, further larger studies taking genetic background into consideration are required to address these questions.
These studies raise many questions regarding the role of the increased frequency of maternal cells in type 1 diabetes. While we have shown that MMc are not infiltrating cells in T1D islets, they could potentially be involved in early events in type 1 diabetes initiation or in the response to islet autoimmunity. Analysis of MMc pancreatic sections from islet autoantibody positive individuals who have not yet developed type 1 diabetes will be required to shed light on this conundrum. Elevated levels of semi-allogeneic maternal cells could potentially trigger the loss of tolerance to self-antigens in autoimmunity. The importance of early life events in susceptibility to type 1 diabetes is increasingly clear [16] and maternal cells have been shown to shape fetal immune development [2]. In the case of autoimmunity, it is unclear whether there is a threshold of MMc level at certain times during fetal immune development that tightly regulates immune balance and whether levels above the threshold could lead to the breakdown of anti-maternal tolerance. The classic model of type 1 diabetes involves initial death of a few beta cells, followed by cascades of epitope spreading and beta cell destruction [17]. Birth cohort studies demonstrate an explosion of islet autoimmunity between 6 months and 3 years of age [18] [19] when islet reorganization is occurring. If loss of maternal immune tolerance occurs, exposure to maternal beta cell alloantigens upon either physiological stress (i.e. beta cell apoptosis during islet remodelling) [20]–[22] or environmental insult could trigger diabetes. It remains to be addressed that whether there are interactions between maternal cells/antigens with host immune cells in the para-pancreatic lymph nodes which may modulate islet autoimmunity. Direct presentation of host beta cell antigens by maternal antigen presenting cells (APC) or indirect presentation of maternal beta cell antigens by host APC may trigger autoimmunity but these hypotheses need to be tested in animal models.
Recent data from a mouse model suggests that MMc could initiate autoimmunity by recognizing fetal antigens. Roy et al. observed that male litters exposed to fetal beta cell specific maternal T cells were predisposed to autoimmune diabetes, but the islet infiltrating lymphocytes were host derived, as we have observed in human type 1 diabetes. They further speculated that maternal T cells may have modified fetal antigen presenting cells towards a more immunogenic self-reactive phenotype [23].
Alternatively, the wide tissue distribution of MMc and the presence of maternal stem cell pools in non-lymphoid tissues [24] led to the suggestion that MMc may participate in tissue regeneration. Whether increased frequencies of MMc result from maternal stem cells contributing to attempted tissue regeneration remains to be proven. Bonner-Weir et al. suggested that ductal cells may transdifferentiate into new islet beta cells [25]. We identified MMc in ductal cells and observed adjacent insulin positive cells but these insulin positive cells were not MMc.
In conclusion, MMc in human pancreas exist in multiple cell subsets. Levels of MMc are increased in type 1 diabetes pancreas with highest levels in T1D islets. This could potentially trigger the loss of anti-maternal immune tolerance and maternal beta cell antigens may serve as immune targets but MMc are not infiltrating immune cells in type 1 diabetes.
Supporting Information
Acknowledgments
This research was performed with the support of the Network for Pancreatic Organ Donors with Diabetes (nPOD), a collaborative type 1 diabetes research project sponsored by JDRF. Organ Procurement Organizations (OPO) partnering with nPOD to provide research resources are listed at www.jdrfnpod.org/our-partners.php. The authors also gratefully acknowledge Dr Alan K Foulis, Department of Pathology, Royal Infirmary, Glasgow, UK for providing paraffin embedded type 1 diabetic pancreases; Prof RR deKrijger, Erasmus Medical Centre, Rotterdam for providing normal pancreases and Prof. Paul Johnson, Nuffield Department of Surgery, University of Oxford, UK for providing isolated human islets.
Funding Statement
This study was funded by a Diabetes United Kingdom PhD studentship to JY. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Ziegler AG, Bonifacio E (2012) Group B-BS (2012) Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 55: 1937–1943. [DOI] [PubMed] [Google Scholar]
- 2. Mold JE, Michaelsson J, Burt TD, Muench MO, Beckerman KP, et al. (2008) Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science 322: 1562–1565. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Burlingham WJ, Grailer AP, Heisey DM, Claas FH, Norman D, et al. (1998) The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors. The New England journal of medicine 339: 1657–1664. [DOI] [PubMed] [Google Scholar]
- 4. Nelson JL (2008) Your cells are my cells. Sci Am 298: 64–71. [PubMed] [Google Scholar]
- 5. Nelson JL (2012) The otherness of self: microchimerism in health and disease. Trends Immunol 33: 421–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Reed AM, McNallan K, Wettstein P, Vehe R, Ober C (2004) Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis? Journal of immunology 172: 5041–5046. [DOI] [PubMed] [Google Scholar]
- 7. Stevens AM, Hermes HM, Rutledge JC, Buyon JP, Nelson JL (2003) Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet 362: 1617–1623. [DOI] [PubMed] [Google Scholar]
- 8. O'Donoghue K, Chan J, de la Fuente J, Kennea N, Sandison A, et al. (2004) Microchimerism in female bone marrow and bone decades after fetal mesenchymal stem-cell trafficking in pregnancy. Lancet 364: 179–182. [DOI] [PubMed] [Google Scholar]
- 9. Nelson JL, Gillespie KM, Lambert NC, Stevens AM, Loubiere LS, et al. (2007) Maternal microchimerism in peripheral blood in type 1 diabetes and pancreatic islet beta cell microchimerism. Proc Natl Acad Sci U S A 104: 1637–1642. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Vanzyl B, Planas R, Ye Y, Foulis A, de Krijger RR, et al. (2010) Why are levels of maternal microchimerism higher in type 1 diabetes pancreas? Chimerism 1: 45–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Ketola I, Otonkoski T, Pulkkinen MA, Niemi H, Palgi J, et al. (2004) Transcription factor GATA-6 is expressed in the endocrine and GATA-4 in the exocrine pancreas. Mol Cell Endocrinol 226: 51–57. [DOI] [PubMed] [Google Scholar]
- 12. Karafin MS, Cummings CT, Fu B, Iacobuzio-Donahue CA (2009) The developmental transcription factor Gata4 is overexpressed in pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol 3: 47–55. [PMC free article] [PubMed] [Google Scholar]
- 13. Gallo R, Gambelli F, Gava B, Sasdelli F, Tellone V, et al. (2007) Generation and expansion of multipotent mesenchymal progenitor cells from cultured human pancreatic islets. Cell Death Differ 14: 1860–1871. [DOI] [PubMed] [Google Scholar]
- 14. Russ HA, Ravassard P, Kerr-Conte J, Pattou F, Efrat S (2009) Epithelial-mesenchymal transition in cells expanded in vitro from lineage-traced adult human pancreatic beta cells. PLoS One 4: e6417. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Ehrie MG, Swartz FJ (1974) Diploid, tetraploid and octaploid beta cells in the islets of Langerhans of the normal human pancreas. Diabetes 23: 583–588. [DOI] [PubMed] [Google Scholar]
- 16. Stene LC, Gale EA (2013) The prenatal environment and type 1 diabetes. Diabetologia [DOI] [PubMed] [Google Scholar]
- 17. van Belle TL, Coppieters KT, von Herrath MG (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91: 79–118. [DOI] [PubMed] [Google Scholar]
- 18. Ziegler AG, Bonifacio E, Grp B-BS (2012) Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 55: 1937–1943. [DOI] [PubMed] [Google Scholar]
- 19. Parikka V, Nanto-Salonen K, Saarinen M, Simell T, Ilonen J, et al. (2012) Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 55: 1926–1936. [DOI] [PubMed] [Google Scholar]
- 20. Trudeau JD, Dutz JP, Arany E, Hill DJ, Fieldus WE, et al. (2000) Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes? Diabetes 49: 1–7. [DOI] [PubMed] [Google Scholar]
- 21. Meier JJ, Butler AE, Saisho Y, Monchamp T, Galasso R, et al. (2008) Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 57: 1584–1594. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Turley S, Poirot L, Hattori M, Benoist C, Mathis D (2003) Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med 198: 1527–1537. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Roy E, Leduc M, Guegan S, Rachdi L, Kluger N, et al. (2011) Specific maternal microchimeric T cells targeting fetal antigens in beta cells predispose to auto-immune diabetes in the child. J Autoimmun 36: 253–262. [DOI] [PubMed] [Google Scholar]
- 24. Dutta P, Burlingham WJ (2010) Stem cell microchimerism and tolerance to non-inherited maternal antigens. Chimerism 1: 2–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Bonner-Weir S, Inada A, Yatoh S, Li WC, Aye T, et al. (2008) Transdifferentiation of pancreatic ductal cells to endocrine beta-cells. Biochem Soc Trans 36: 353–356. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.